1. Home
  2. AKBA vs UIS Comparison

AKBA vs UIS Comparison

Compare AKBA & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$3.16

Market Cap

220.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
UIS
Founded
2007
1942
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
220.2M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
AKBA
UIS
Price
$1.22
$3.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.67
$5.67
AVG Volume (30 Days)
4.1M
927.3K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$1,950,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.97
52 Week High
$3.81
$4.98

Technical Indicators

Market Signals
Indicator
AKBA
UIS
Relative Strength Index (RSI) 46.66 34.69
Support Level $1.16 $2.59
Resistance Level $1.52 $3.29
Average True Range (ATR) 0.07 0.28
MACD -0.02 -0.08
Stochastic Oscillator 7.59 1.65

Price Performance

Historical Comparison
AKBA
UIS

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: